191
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4

, , , , &
Pages 453-459 | Received 08 Jan 2015, Accepted 03 Jul 2015, Published online: 14 Aug 2015
 

Abstract

Antibodies against aquaporin-4 (AQP4) are specific and pathogenetic for Neuromyelitis Optica (NMO). In a previous study, three linear intracellular AQP4 B-cell epitopes were uncovered in NMO patients. A particular epitope showed high-sequence similarity with a segment of the human TAX1BP1 protein, which is necessary for the replication of HTLV-1 virus. The aim of the present study was to investigate whether immunization of mice with the TAX1BP1 peptide could produce specific antibodies against AQP4 epitopes or induce symptoms. Eight C57Bl/6 mice were immunized with TAX1BP1pep in Complete Freund’s Adjuvant and eight with adjuvant only. Animals received three subcutaneous injections and sera were obtained before each immunization and at sacrifice. All sera were evaluated by ELISA for antibodies against the TAX1BP1peptide, the homologous AQP4 peptide and all linear AQP4 epitopes. Homologous and cross-inhibition assays were performed to ensure binding specificity, and reactivity against conformational AQP4 epitopes was evaluated by a cell-based assay. Sera from immunized animals showed high reactivity against the immunization peptide, and the homologous AQP4 epitope. Inhibition assays confirmed binding specificity. No antibodies were produced against any other epitopes, either linear or conformational. No clinical or brain inflammatory signs were observed in the animals. The induction of antibodies to an AQP4 epitope in mice immunized with the TAX1BP1-derived peptide suggests that a latent HTLV-1 infection could lead to TAX1BP1 antigen presentation and the production of anti-AQP4 antibodies, probably through T cell-mediated mechanisms. Further studies are needed for exploring triggering factors for NMO especially in HTLV-1-endemic regions.

Acknowledgements

Dr E. Kampylafka performed experiments, analyzed data and drafted the manuscript. Dr H. Alexopoulos analyzed data, co-supervised experimental work and critically revised the manuscript. Dr A. El Hamidieh performed experiments. Prof. M. Dalakas co-supervised experimental work and critically revised the manuscript. Dr E. Andreakos co-supervised experimental work and critically revised the manuscript. Prof. A.G. Tzioufas conceived the project, co-supervised experimental work and critically revised the manuscript.

E.A. is supported by the FP7 Programme of the European Commission (PreDicta, RiskyCAD, AtheroFlux) and the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF) co-financed by the European Union and Greek national funds (Midas, Resolve-Asthma).

Declaration of interest

The authors report no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.